BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

...Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR...
BioCentury | Jul 20, 2009
Company News

Carmot, CV Ingenuity, FibroGen, Gemmus Pharma, Osprey Pharmaceuticals U.S.A., Solidus, California Institute for Quantitative Biosciences other news

...Francisco, Calif. FibroGen Inc. , San Francisco, Calif. Gemmus Pharma Inc. , San Francisco, Calif. Osprey Pharmaceuticals U.S.A. Inc....
BioCentury | Apr 20, 2009
Clinical News

CCL2-LPM: Phase Ib started

...open-label, dose-escalation, Canadian Phase Ib trial to evaluate intravenous CCL2-LPM in up to 30 patients. Osprey Pharmaceuticals U.S.A. Inc....
Items per page:
1 - 3 of 3
BioCentury | Oct 11, 2010
Company News

NKT Therapeutics management update

...Inflammation, Cancer, Autoimmune Hired: Barbara Finck as CMO, formerly SVP of R&D and CMO at Osprey Pharmaceuticals U.S.A. Inc. WIR...
BioCentury | Jul 20, 2009
Company News

Carmot, CV Ingenuity, FibroGen, Gemmus Pharma, Osprey Pharmaceuticals U.S.A., Solidus, California Institute for Quantitative Biosciences other news

...Francisco, Calif. FibroGen Inc. , San Francisco, Calif. Gemmus Pharma Inc. , San Francisco, Calif. Osprey Pharmaceuticals U.S.A. Inc....
BioCentury | Apr 20, 2009
Clinical News

CCL2-LPM: Phase Ib started

...open-label, dose-escalation, Canadian Phase Ib trial to evaluate intravenous CCL2-LPM in up to 30 patients. Osprey Pharmaceuticals U.S.A. Inc....
Items per page:
1 - 3 of 3